Does KPV need a reducing agent?

No — there is no cysteine in the sequence.

Why might I recover less than expected?

Adsorption to glass and plastic. A small, positively charged molecule binds surfaces, and at low quantities that loss is significant.

Is KPV unusually stable?

Chemically, yes — no cysteine, methionine or asparagine, and only two hydrolysable bonds. Physical loss is the more likely problem.

KPV

KPV Storage and Handling

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

KPV is supplied lyophilised and most stable dry, cold and dark. With no cysteine, methionine or asparagine, the common chemical degradation routes do not apply — leaving hydrolysis and, more practically, physical loss through adsorption to container surfaces.

Key facts

Supplied as: White lyophilised powder
Disulfide risk: None — no cysteine
Oxidation risk: None — no methionine
Deamidation: No asparagine
Protease resistance: Aided by proline
Main practical loss: Adsorption to surfaces

Chemically among the simplest

Three residues, none of them carrying a reactive functional group beyond lysine's amine. No thiol to oxidise or scramble, no thioether, no amide side chain prone to deamidation. Two peptide bonds is the entire hydrolysable content of the molecule. As research peptides go, KPV is close to inert.

Why adsorption matters more here

A small, positively charged molecule binds readily to glass and plastic surfaces. At the low absolute quantities a 342 Da compound is often used in, the fraction lost to a vial wall and pipette tips can be a substantial share of the material — and it is a silent loss, since what remains is chemically intact. Low-binding consumables and minimal transfers are the practical response.

Research material referenced

KPV 10mg — third-party HPLC tested

View — £24.99

The proline contribution

Proline-adjacent peptide bonds resist most peptidases, and in a three-residue peptide one proline covers a large proportion of the available bonds. That gives real enzymatic stability, though it does nothing against simple chemical hydrolysis in solution over time.

Reconstitution

Introduce diluent gently down the vial wall and swirl rather than shake. KPV is small and highly soluble, so it dissolves readily and vigorous agitation is never needed. Foaming indicates an air-liquid interface has been created, which is where peptides denature — less of a concern for a molecule this small and unstructured than for a lipidated 39-mer, but still avoidable.

After reconstitution

Aliquot into single-use volumes rather than freeze-thawing. The chemical robustness that protects KPV against oxidation does nothing about the physical stresses of repeated cycling, and for a compound this prone to surface adsorption, minimising handling steps is the more important discipline.

Extended research context

The KPV deep dive

Deep dive: two functions in one hormone, and the case for splitting them

Alpha-MSH is a thirteen-residue peptide cleaved from proopiomelanocortin, and it does two things that have almost nothing to do with each other. Its core sequence engages melanocortin receptors on melanocytes and drives melanin synthesis - the activity it is named for. Separately, it carries anti-inflammatory activity that Brzoska and colleagues localised to its C-terminal end, a paper titled 'terminal signal' precisely because the finding was that the signal sits at the terminus rather than in the receptor-binding core. That is an unusually clean functional separation, and it produced two research compounds pulling in opposite directions from one parent. KPV takes the C-terminal three residues and discards the pigmentation activity. Melanotan II does the reverse - a cyclic analogue built around the receptor-binding portion to maximise exactly what KPV was designed to leave behind. Same hormone, opposite halves.

Deep dive: what happens when you shrink a molecule fivefold

Going from alpha-MSH at 1,664.9 Da to KPV at 342.43 Da is not a trim, it is a change of category. A 1,665 Da peptide is firmly a cell-surface ligand - far too large to cross a membrane passively, so whatever it does must begin at a receptor. A 342 Da tripeptide is small enough that intracellular access becomes plausible, which is why KPV's reported mechanism is described in terms of NF-kappaB signalling rather than melanocortin receptor engagement. The consequence is rarely stated: if the fragment acts inside the cell and the parent acts at its surface, then the anti-inflammatory activity of the two is not necessarily the same phenomenon, and read-across between them should run cautiously in both directions. Fragment logic assumes the fragment is the parent minus something. Here it may be the parent minus something plus a different route of access.

Deep dive: the delivery paper is the most informative thing in the literature

Xiao and colleagues published in Molecular Therapy in 2017 on delivering KPV orally using hyaluronic acid-functionalised nanoparticles targeted to inflamed intestinal tissue. Read as a result it is a delivery success. Read as a statement about the compound it is more interesting: nobody builds a targeted nanoparticle carrier for a molecule that already reaches its target. The existence of that work says the free tripeptide's arrival at inflamed tissue was the limiting problem - which follows directly from being 342 Da, highly soluble and rapidly cleared. It is the same signal that CJC-1295's DAC modification carries for growth hormone secretagogues, or that lipidation carries across the whole incretin class: when the engineering effort goes into getting a compound to stay and arrive rather than into making it more active, the pharmacokinetics were the bottleneck.

Research applications

▸Melanocortin fragment structure-activity research
▸NF-kappaB pathway and cytokine production studies in culture
▸Murine models of induced intestinal inflammation
▸Targeted peptide delivery and carrier system development
▸Comparative work on parent hormones and isolated fragments
▸Analytical method development for very short peptides

Handling checklist

✓Verify identity against Lys-Pro-Val, CID 125672, at 342.43 Da
✓Do not search PubChem for 'KPV' - it returns an unrelated organic acid
✓Store lyophilised, cold, dry and dark
✓Use low-binding consumables; a small cationic peptide adsorbs to surfaces
✓Reconstitute gently down the vial wall and swirl, never shake
✓Aliquot into single-use volumes to avoid freeze-thaw cycling
✓Expect no disulfide or oxidation satellites - no cysteine, no methionine

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Searching PubChem for 'KPV' to verify a certificate

Fix: That returns CID 13294447, 2-oxo-5-phenylpentanoic acid at 192.21 Da, an unrelated compound. Search Lys-Pro-Val for CID 125672.

✗ Treating KPV and alpha-MSH findings as interchangeable

Fix: They differ fivefold in mass and the fragment may act intracellularly where the parent cannot. Read across cautiously in both directions.

✗ Assuming a colitis model result speaks to inflammatory bowel disease

Fix: Induced colitis in a mouse is acute and chemical; human IBD is chronic, heterogeneous and immunologically complex.

✗ Expecting to quantify KPV by absorbance at 280 nm

Fix: There is no aromatic residue in the sequence, so there is no usable absorbance there.

✗ Attributing unexplained low recovery to degradation

Fix: KPV is chemically robust - no cysteine, methionine or asparagine. Adsorption to glass and plastic is the more likely cause.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Does KPV need a reducing agent?: No — there is no cysteine in the sequence.
Why might I recover less than expected?: Adsorption to glass and plastic. A small, positively charged molecule binds surfaces, and at low quantities that loss is significant.
Is KPV unusually stable?: Chemically, yes — no cysteine, methionine or asparagine, and only two hydrolysable bonds. Physical loss is the more likely problem.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum